The table below shows Candel Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$38.31M
-$27.02M
-$34.24M
-$31.42M
-$22.22M
-$9.07M
Capital expenditure
$587.00K
$16.00K
$457.00K
$1.30M
$1.83M
$1.48M
Investing cash flow
-$560.00K
-$16.00K
-$280.00K
-$1.30M
-$1.83M
$38.45M
Dividends paid
-
-
-
-
CADL operating cash flow (10-K history)
Candel Therapeutics, Inc. reported operating cash flow of -$38.31M for fiscal year 2025. That is down 41.8% from -$27.02M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$9.07M (FY 2020) to -$38.31M. Figures come from the company's audited annual reports as filed with the SEC.